SPTLC1 Antibody (49): sc-136076
- SPTLC1 Antibody (49) is a mouse monoclonal IgG1, cited in 3 publications, provided at 50 µg/500 µl
- raised against amino acids 121-238 of SPTLC1 of mouse origin
- recommended for detection of SPTLC1 of mouse, rat and human origin by WB, IP and IF
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for SPTLC1 Antibody (49). This work is in progress.
QUICK LINKS
SPTLC1 Antibody (49) is a mouse monoclonal IgG1 antibody that detects SPTLC1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). SPTLC1, also known as serine palmitoyltransferase 1, plays a crucial role in sphingolipid biosynthesis by catalyzing the conversion of L-serine and palmitoyl-CoA into 3-oxosphinganine, a key precursor in the formation of complex sphingolipids. This process is vital for maintaining cellular membrane integrity and signaling, as sphingolipids are essential components of cell membranes and are involved in various cellular processes, including apoptosis, cell growth, and differentiation. Notably, SPTLC1 activity is regulated by the availability of pyridoxal 5′-phosphate cofactor, and SPTLC1 expression can be upregulated in response to increased transepidermal water loss, highlighting its importance in skin barrier function. Deficiencies in SPTLC1, along with SPTLC2, can lead to serious health conditions such as hereditary sensory neuropathy, atopic eczema, and psoriasis, underscoring SPTLC1 significance in both normal physiology and disease states. Anti-SPTLC1 antibody (49) serves as an invaluable tool for researchers investigating the role of sphingolipid metabolism in various biological contexts.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
SPTLC1 Antibody (49) References:
- Decreased SPTLC1 expression predicts worse outcomes in ccRCC patients. | Zhu, WK., et al. 2020. J Cell Biochem. 121: 1552-1562. PMID: 31512789
- SPTLC1 inhibits cell growth via modulating Akt/FOXO1 pathway in renal cell carcinoma cells. | Kong, Z., et al. 2019. Biochem Biophys Res Commun. 520: 1-7. PMID: 31554600
- Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. | Johnson, JO., et al. 2021. JAMA Neurol. 78: 1236-1248. PMID: 34459874
- SPTLC1 variants associated with ALS produce distinct sphingolipid signatures through impaired interaction with ORMDL proteins. | Lone, MA., et al. 2022. J Clin Invest. 132: PMID: 35900868
- The SPTLC1 p.S331 mutation bridges sensory neuropathy and motor neuron disease and has implications for treatment. | Fiorillo, C., et al. 2022. Neuropathol Appl Neurobiol. 48: e12842. PMID: 35904184
- Murine endothelial serine palmitoyltransferase 1 (SPTLC1) is required for vascular development and systemic sphingolipid homeostasis. | Kuo, A., et al. 2022. Elife. 11: PMID: 36197001
- Clinical feature difference between juvenile amyotrophic lateral sclerosis with SPTLC1 and FUS mutations. | Wang, P., et al. 2023. Chin Med J (Engl). 136: 176-183. PMID: 36801857
- Mutation screening of SPTLC1 and SPTLC2 in amyotrophic lateral sclerosis. | Li, C., et al. 2023. Hum Genomics. 17: 28. PMID: 36966328
- Functional and Molecular Characterization of New SPTLC1 Missense Variants in Patients with Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1). | Rochat, J., et al. 2024. Genes (Basel). 15: PMID: 38927628
- Genetic and functional analyses of SPTLC1 in juvenile amyotrophic lateral sclerosis. | Okubo, S., et al. 2024. J Neurol. 272: 36. PMID: 39666121
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SPTLC1 Antibody (49) | sc-136076 | 50 µg/500 µl | $316.00 |